Contributors |
|
xi | |
Preface |
|
xiii | |
Acknowledgments |
|
xv | |
|
1 Novel therapeutic approaches targeting oxidative stress in mood disorders |
|
|
|
|
|
|
|
|
|
|
1 | (2) |
|
2 The production of ROS in the brain |
|
|
3 | (1) |
|
3 The elimination of ROS in the brain |
|
|
4 | (2) |
|
4 Oxidative stress in the brain |
|
|
6 | (1) |
|
5 Markers of oxidative stress and mood disorders |
|
|
7 | (1) |
|
6 Antioxidant treatments in mood disorders |
|
|
8 | (4) |
|
|
12 | (7) |
|
|
13 | (6) |
|
2 Ferroptosis: Oxidative stress and pathophysiology |
|
|
|
|
|
|
|
19 | (3) |
|
|
22 | (1) |
|
|
23 | (4) |
|
|
24 | (1) |
|
|
24 | (3) |
|
3 Oxidative stress and its biological significance |
|
|
|
|
|
27 | (1) |
|
2 Oxidative stress in 4-hydroxynonenal (HNE) leading to apoptosis |
|
|
28 | (1) |
|
3 Antioxidant supplementation increasing tumorigenesis |
|
|
29 | (1) |
|
4 Regulation of the cell cycle in the oxidative state |
|
|
30 | (1) |
|
5 Viral infections and oxidative stress |
|
|
31 | (1) |
|
6 Epigenetic factors and carcinogenesis |
|
|
31 | (1) |
|
7 Extracellular superoxide angles and apoptosis |
|
|
32 | (11) |
|
8 Extreme oxidative stress with T cells |
|
|
43 | (1) |
|
9 Oxidative stress in lung cancer |
|
|
43 | (1) |
|
10 Inflammation and lung cancer |
|
|
44 | (14) |
|
11 Oxidative stress in breast cancer |
|
|
58 | (6) |
|
|
64 | (13) |
|
|
67 | (10) |
|
4 Novel therapeutic approaches targeting oxidative stress in aging |
|
|
|
|
|
|
77 | (1) |
|
|
78 | (1) |
|
|
78 | (1) |
|
4 Age-associated diseases |
|
|
79 | (3) |
|
5 Novel therapeutic approaches |
|
|
82 | (3) |
|
|
85 | (3) |
|
|
88 | (5) |
|
|
88 | (5) |
|
5 Novel therapeutic approaches targeting oxidative stress in neurodegenerative diseases |
|
|
|
|
|
|
|
|
93 | (1) |
|
2 Dimensions of aging in the investigation of neurodegeneration |
|
|
94 | (11) |
|
|
105 | (7) |
|
4 Implications for research |
|
|
112 | (7) |
|
|
112 | (1) |
|
|
112 | (7) |
|
6 The role of oxidative stress in kidney diseases |
|
|
|
|
|
119 | (1) |
|
2 Kidney architecture at the cellular level |
|
|
120 | (2) |
|
3 Nephrotoxicity and renal pathology |
|
|
122 | (1) |
|
4 Classification of kidney diseases |
|
|
123 | (1) |
|
5 The chemical species of oxidative stress |
|
|
124 | (2) |
|
6 Cellular antioxidant defense system |
|
|
126 | (1) |
|
7 Sources of ROS in the kidneys |
|
|
127 | (1) |
|
8 Reactive oxygen species and kidney diseases |
|
|
128 | (1) |
|
9 Oxidative stress in the renal tubules |
|
|
129 | (4) |
|
10 Oxidative stress in the glomerulus |
|
|
133 | (1) |
|
11 Oxidative stress in the renal vasculature |
|
|
133 | (2) |
|
12 Role of ROS in ischemia and reperfusion (I/R)-induced acute kidney injury |
|
|
135 | (8) |
|
|
135 | (8) |
|
7 The role of oxidative stress and antioxidants across the spectrum of acute coronary syndrome |
|
|
|
|
|
|
|
143 | (1) |
|
|
144 | (1) |
|
3 Endothelial dysfunction and oxidative stress |
|
|
145 | (1) |
|
4 Molecular effects of oxidative stress |
|
|
145 | (1) |
|
5 Oxidative stress in coronary artery disease |
|
|
146 | (1) |
|
6 Coronary microvascular dysfunction |
|
|
147 | (1) |
|
7 Oxidative stress and lipids, protein, and DNA damage |
|
|
147 | (1) |
|
8 Therapies for oxidative stress-associated cardiovascular diseases |
|
|
148 | (4) |
|
|
152 | (3) |
|
|
152 | (3) |
|
8 Biosensors in the detection of oxidative stress using discovered biomarkers |
|
|
|
|
|
|
155 | (1) |
|
|
156 | (4) |
|
|
160 | (2) |
|
4 Overview of discovered biomarkers for oxidative stress |
|
|
162 | (1) |
|
5 Management of oxidative stress conditions |
|
|
163 | (2) |
|
6 Research trends and future challenges in development of biosensors |
|
|
165 | (1) |
|
|
166 | (5) |
|
|
166 | (1) |
|
|
166 | (5) |
|
9 Biochemical approaches/methods in the detection of free radicals |
|
|
|
|
|
|
171 | (1) |
|
|
172 | (1) |
|
3 Chemiluminescence-derived methods using luciferine derivatives |
|
|
173 | (3) |
|
4 Reduction of cytochrome c |
|
|
176 | (1) |
|
|
177 | (1) |
|
|
177 | (1) |
|
|
178 | (1) |
|
|
179 | (1) |
|
9 Redox potential of the GSH/GSSG couple |
|
|
179 | (1) |
|
10 Measurement of F2-isoprostanes as indicators of lipid peroxidation |
|
|
180 | (1) |
|
|
180 | (1) |
|
12 Fluorescent protein-based methods |
|
|
181 | (2) |
|
|
183 | (1) |
|
14 Fluorescence-dependent methods |
|
|
184 | (1) |
|
15 Electron spin resonance (ESR) or electron paramagnetic resonance (EPR) spectroscopy |
|
|
185 | (1) |
|
16 Spin trapping technique |
|
|
186 | (1) |
|
17 Immuno-spin trapping of macromolecules |
|
|
186 | (2) |
|
18 Combined 1ST and mMRI detection |
|
|
188 | (1) |
|
|
188 | (2) |
|
20 Chromatography-based techniques |
|
|
190 | (1) |
|
21 Other biochemical methods |
|
|
191 | (2) |
|
|
193 | (7) |
|
|
193 | (7) |
|
10 Novel therapeutic approaches targeting oxidative stress in breast and lung cancer |
|
|
|
|
|
|
|
200 | (1) |
|
2 Epidemiology and risk factors |
|
|
201 | (8) |
|
3 Role of oxidative stress in cancer pathophysiology |
|
|
209 | (4) |
|
4 Classification of breast and lung cancer |
|
|
213 | (5) |
|
5 Conventional therapies for cancer treatment |
|
|
218 | (14) |
|
6 Novel approaches for cancer therapeutics |
|
|
232 | (8) |
|
7 Therapeutic approaches targeting oxidative stress in cancer |
|
|
240 | (5) |
|
|
245 | (1) |
|
|
245 | (6) |
|
|
246 | (1) |
|
|
246 | (5) |
|
11 Advancements in novel drug delivery systems: Providing a challenge and threat to oxidative stress in various diseases |
|
|
|
|
|
|
|
251 | (2) |
|
2 Antioxidants working principle and pathways |
|
|
253 | (2) |
|
3 Types of antioxidants and their mode of action |
|
|
255 | (3) |
|
|
258 | (1) |
|
5 Innovative approaches in nano delivery of natural and synthetic antioxidants |
|
|
259 | (1) |
|
6 Limitations and future perspectives of novel drug delivery systems at clinical translation level |
|
|
260 | (3) |
|
|
263 | |
|
|
264 | (2) |
|
|
266 | |